TABLE 2.
Uni- and Multivariable Cox Model of Clinical Variables Associated With OS
| Clinical Variable | Hazard Ratio (95% CI) | P Value |
|---|---|---|
|
| ||
| Univariate analysis* | ||
| γδ T-cell-specific genes (LR vs. HR) | 0.57 (0.40–0.83) | 0.003 |
| Age (>50 vs. <50) | 1.11 (0.77–1.60) | 0.567 |
| Sex (female vs. male) | 0.49 (0.26–0.95) | 0.033 |
| HBV (AVR-CC vs. CC) | 1.11 (0.72–1.72) | 0.627 |
| Cirrhosis (yes vs. no) | 3.35 (1.24–9.09) | 0.017 |
| Child- Pugh score (B vs. A) | 1.37 (0.81–2.31) | 0.243 |
| AFP (elevated vs. normal) | 1.35 (0.94–1.95) | 0.103 |
| CA 19–9 (elevated vs. normal) | 1.61 (1.12–2.33) | 0.010 |
| Tumor size (≥3 vs. <3 cm) | 2.20 (1.46–3.31) | <0.001 |
| Multinodular (yes vs. no) | 1.47 (0.97–2.23) | 0.067 |
| Microvascular invasion (yes vs.no) | 1.76 (1.18–2.62) | 0.006 |
| CLIP staging (late vs. early) | 2.34 (1.46–3.77) | <0.001 |
| Okuda staging (1 vs. 0) | 1.62 (0.99–2.64) | 0.051 |
| TNM staging | ||
| I | ref.† | — |
| II | 1.95 (0.69–5.23) | 0.209 |
| III | 3.09 (1.83–5.21) | <0.001 |
| BCLC stage | ||
| 0 | ref. | — |
| A | 3.70 (1.16–11.77) | 0.027 |
| B | 7.83 (2.26–27.14) | 0.001 |
| C | 12.89 (3.84–43.20) | <0.001 |
| Multivariate analysis‡ | ||
| γδ T-cell-specific genes (LR vs. HR) | 0.49 (0.32–0.76) | 0.001 |
| Sex (female vs. male) | 0.53 (0.26–1.11) | 0.091 |
| Cirrhosis (yes vs. no) | 2.06 (0.73–5.83) | 0.175 |
| CA 19–9 (elevated vs. normal) | 2.08 (1.37–3.16) | 0.001 |
| Microvascular invasion (yes vs.no) | 1.46 (0.96–2.20) | 0.074 |
| BCLC stage | ||
| 0 | ref. | — |
| A | 4.80 (1.48–15.56) | 0.009 |
| B | 9.29 (2.58–33.45) | 0.001 |
| C | 14.89 (4.32–51.25) | <0.001 |
| Multivariate analysis§ | ||
| γδ T-cell-specific genes (LR vs. HR) | 0.53 (0.30–0.95) | 0.035 |
| Sex (female vs. male) | 0.38 (0.12–1.18) | 0.094 |
| Cirrhosis (yes vs. no) | 0.45 (0.09–2.24) | 0.330 |
| CA 19–9 (elevated vs. normal) | 1.56 (0.85–2.87) | 0.149 |
| Microvascular invasion (yes vs. no) | 1.60 (0.87–2.94) | 0.133 |
| TNM staging | ||
| I | ref. | — |
| II | 0.81 (0.10–6.43) | 0.842 |
| III | 2.99 (1.61–5.55) | <0.001 |
| Multivariate analysis|| | ||
| γδ T-cell-specific genes (LR vs. HR) | 0.59 (0.38–0.90) | 0.015 |
| Sex (female vs. male) | 0.47 (0.23–0.97) | 0.042 |
| Cirrhosis (yes vs. no) | 1.75 (0.64–4.86) | 0.277 |
| CA 19–9 (elevated vs. normal) | 2.35 (1.14–4.88) | 0.021 |
| Tumor size (≥3 vs. >3 cm) | 1.88 (1.20–2.95) | 0.006 |
| Microvascular invasion (yes vs. no) | 1.46 0.95–2.19) | 0.082 |
| CLIP staging (late vs. early) | 2.35 (1.14–4.88) | 0.021 |
†
ref = reference variable. Multivariate analysis, Cox proportional hazards regression adjusting for sex, cirrhosis, CA 19–9, tumor size, and microvascular invasion.
‡
BCLC staging.
§
TNM staging.
||
CLIP staging.
Bold indicates significant value (P < 0.05).
Abbreviations: AVR-CC,active viral replication chronic carrier; CC, chronic carrier; HR, high risk; LR, low risk.